Rockwell Collins, Inc. (COL) EPS Estimated At $1.75; ABATTIS BIOCEUTICALS ORDINARY SHAR (ATTBF) Sellers Decreased By 97.45% Their Shorts

April 17, 2018 - By Marie Mckinney

Rockwell Collins, Inc. (NYSE:COL) Logo

ABATTIS BIOCEUTICALS CORP ORDINARY SHAR (OTCMKTS:ATTBF) had a decrease of 97.45% in short interest. ATTBF’s SI was 4,500 shares in April as released by FINRA. Its down 97.45% from 176,500 shares previously. The stock increased 2.72% or $0.0051 during the last trading session, reaching $0.1926. About shares traded. Abattis Bioceuticals Corp. (OTCMKTS:ATTBF) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect Rockwell Collins, Inc. (NYSE:COL) to report $1.75 EPS on April, 27 before the open.They anticipate $0.41 EPS change or 30.60% from last quarter’s $1.34 EPS. COL’s profit would be $286.91M giving it 19.24 P/E if the $1.75 EPS is correct. After having $1.59 EPS previously, Rockwell Collins, Inc.’s analysts see 10.06% EPS growth. The stock increased 0.67% or $0.89 during the last trading session, reaching $134.66. About 1.05M shares traded. Rockwell Collins, Inc. (NYSE:COL) has risen 39.79% since April 17, 2017 and is uptrending. It has outperformed by 28.24% the S&P500.

Among 23 analysts covering Rockwell Collins (NYSE:COL), 5 have Buy rating, 1 Sell and 17 Hold. Therefore 22% are positive. Rockwell Collins had 74 analyst reports since July 28, 2015 according to SRatingsIntel. RBC Capital Markets maintained Rockwell Collins, Inc. (NYSE:COL) rating on Friday, May 26. RBC Capital Markets has “Hold” rating and $11400 target. The rating was downgraded by Canaccord Genuity to “Hold” on Tuesday, July 26. The firm has “Hold” rating given on Tuesday, January 23 by RBC Capital Markets. Robert W. Baird downgraded Rockwell Collins, Inc. (NYSE:COL) rating on Wednesday, September 13. Robert W. Baird has “Neutral” rating and $140 target. Cowen & Co maintained Rockwell Collins, Inc. (NYSE:COL) on Friday, July 28 with “Buy” rating. The stock of Rockwell Collins, Inc. (NYSE:COL) has “Overweight” rating given on Monday, January 25 by Barclays Capital. The rating was maintained by RBC Capital Markets with “Hold” on Sunday, October 8. The stock of Rockwell Collins, Inc. (NYSE:COL) has “Outperform” rating given on Wednesday, April 19 by Robert W. Baird. The firm has “Overweight” rating by Morgan Stanley given on Monday, March 13. The firm has “Overweight” rating given on Thursday, August 17 by Morgan Stanley.

Rockwell Collins, Inc. designs, produces, and supports communications and aviation systems worldwide. The company has market cap of $22.08 billion. The Company’s Commercial Systems segment provides integrated avionics systems; cabin management systems; data link, high frequency, very high frequency, and satellite communications systems; landing sensors, radio navigation, and geophysical sensors, as well as flight management systems; situational awareness and surveillance systems and products; integrated flight controls; simulation and training systems; and maintenance, repair, parts, and after-sales support services, as well as aftermarket used equipment. It has a 24.96 P/E ratio. This segment serves original equipment manufacturers of commercial air transport, business and regional aircraft, commercial airlines, and business aircraft operators.

Investors sentiment decreased to 0.73 in Q4 2017. Its down 0.19, from 0.92 in 2017Q3. It dropped, as 56 investors sold Rockwell Collins, Inc. shares while 221 reduced holdings. 57 funds opened positions while 146 raised stakes. 103.89 million shares or 8.02% less from 112.95 million shares in 2017Q3 were reported. 1St Source Fincl Bank accumulated 1,500 shares. Cap Fincl Advisers Limited Liability Corp reported 0.01% of its portfolio in Rockwell Collins, Inc. (NYSE:COL). The California-based California State Teachers Retirement Sys has invested 0.08% in Rockwell Collins, Inc. (NYSE:COL). Notis holds 0.23% or 2,915 shares in its portfolio. Leucadia National has 80,000 shares for 0.83% of their portfolio. Commonwealth Of Pennsylvania School Empls Retrmt Systems accumulated 122,214 shares. Lombard Odier Asset Mgmt (Europe) Ltd reported 0.02% in Rockwell Collins, Inc. (NYSE:COL). Perella Weinberg Prns Cap Mgmt L P has invested 1.9% of its portfolio in Rockwell Collins, Inc. (NYSE:COL). Live Your Vision Llc stated it has 292 shares or 0.01% of all its holdings. Sabal Trust Com holds 3,722 shares or 0.05% of its portfolio. Pillar Pacific Lc holds 2,090 shares. Us National Bank De stated it has 0.02% in Rockwell Collins, Inc. (NYSE:COL). Frontier Invest stated it has 0.02% in Rockwell Collins, Inc. (NYSE:COL). 55,743 were accumulated by Balyasny Asset Ltd Llc. Moreover, Quantitative Systematic Strategies Llc has 0.08% invested in Rockwell Collins, Inc. (NYSE:COL).

Since December 18, 2017, it had 0 insider purchases, and 2 sales for $3.87 million activity. ALLEN PATRICK E sold 25,410 shares worth $3.43 million. $443,745 worth of Rockwell Collins, Inc. (NYSE:COL) was sold by STENSKE DOUGLAS E on Monday, December 18.

Abattis Bioceuticals Corp., a biotechnology company, develops, licenses, and markets health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets in Canada. The company has market cap of $71.13 million. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and bioceutical marketing services in the area of health products. It currently has negative earnings. The firm was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corp. in September 2012.

Rockwell Collins, Inc. (NYSE:COL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: